Moshkevich Solomon, President of Clinical Diagnostics, has demonstrated a pronounced selling bias in his recent insider trading activity, as reflected in SEC Form 4 filings. Over the course of 63 transactions, Solomon has exclusively engaged in selling shares of Natera, Inc. (NTRA), with no recent purchases recorded. His total sell value amounts to $14,269,405.44, significantly outweighing his total buy value of $263,734.59. This trend is particularly evident in his 18 most recent trades, all of which were sales executed between January 2026 and March 2026. Notably, on January 20, 2026, Solomon sold shares worth $5,447,104.57, marking the largest single transaction in this period. Other significant sales include $1,082,714.19 on December 12, 2025, and $318,971.04 on March 2, 2026. Smaller transactions, such as $18,280 on February 2, 2026, and $68,855 on January 21, 2026, further underscore the consistent pattern of divestment. Solomon’s trading activity suggests a deliberate reduction in his holdings of NTRA shares, with no indication of recent acquisitions. This focus on selling aligns with his broader transactional history, which reveals a clear preference for liquidating his position in Natera over accumulating additional shares.
AI-assisted summary